Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Sponsor
Yonsei University
Study ID
NCT00801385
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib hydrochloride — DRUG
  • sorafenib tosylate — DRUG
  • DNA analysis — GENETIC
  • mutation analysis — GENETIC
  • polymerase chain reaction — GENETIC
  • protein analysis — GENETIC
  • protein expression analysis — GENETIC
  • immunohistochemistry staining method — OTHER
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.

Key Dates

First listed
Dec 3, 2008
Start date
Sep 30, 2008
Status verified
Aug 2009
Primary completion
Jun 30, 2009

Study Design

Enrollment
47 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Tumor response based on RECIST criteria

Related Studies